Navigation Links
S1 Pharmaceuticals Appoints Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to Its Scientific Advisory Board
Date:10/24/2011

JERSEY CITY, N.J., Oct. 24, 2011 /PRNewswire/ -- S1 Pharmaceuticals, Inc. (S1) today announced that it has appointed Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to its Scientific Advisory Board.  Dr. Segraves and Dr. Pyke will help guide the clinical development of S1's lead product, Lorexys, as it prepares for Phase I clinical trials.

"We are pleased to be able to attract such knowledgeable and prominent individuals as Segraves and Pyke to participate as members of our Scientific Advisory Board," stated Nicolas G. Sitchon, MA, MBA, Chief Executive Officer of S1 Pharmaceuticals.  "The formation of a distinguished advisory board to provide medical, clinical, and strategic guidance to the Company marks the next step in the evolution of our Lorexys clinical development program."

Dr. Segraves is a professor of psychiatry at Case Western Reserve School of Medicine.  Among his scientific interests are the treatment of sexual disorders, the co-morbidity of sexual dysfunction with anxiety and depressive disorders, sexual side effects of pharmacological agents, and pharmacotherapy of sexual disorders.  Dr. Segraves has authored over 200 publications in the area of human sexuality, numerous international presentations, and five texts.  He sits on the editorial board of the International Journal of Impotence Research and is the current editor of the Journal of Sex and Marital Therapy.  Dr. Segraves obtained his M.D. from Vanderbilt University, his PhD from the University of London, and completed his residency in psychiatry at the University of Chicago.

Dr. Pyke served as Director of Clinical Research at Boehringer Ingelheim Pharmaceuticals where he led the Flibanserin Worldwide premenopausal HSDD clinical program that ended in October 2010.  Dr. Pyke has a distinguished career of leading drug after drug to FDA approval with Parke-Davis, Bristol-Myers Squibb, and Upjohn.  He has continued his clinical practice treating anxiety, depression, and substance abuse.  Dr. Pyke is a member of numerous societies, including the International Society for the Study of Women's Sexual Health.  He completed his Ph.D. at the University of Wisconsin, Madison, obtained his M.D. at the University of Miami, and completed his medical training in Internal Medicine at the University of Michigan.

"I look forward to serving on the advisory board for this promising potential therapy," stated Pyke. "The field of sexual health is ever evolving and it's exciting to join a company that is on the leading edge of this evolution."

About S1 Pharmaceuticals, Inc.
S1 is an early-stage biopharmaceutical company developing therapeutic solutions for disorders of Women's Sexual Health.  The most common type of Female Sexual Dysfunction (FSD) is a loss of libido and lack of sexual interest known as Hypoactive Sexual Desire Disorder (HSDD).  S1 is developing its lead product, Lorexys, as an oral drug and will seek to demonstrate that Lorexys can be the first safe and effective treatment approved by the FDA for HSDD in women.

Contact:
press@s1pharma.com
(201) 839-0941


'/>"/>
SOURCE S1 Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
2. Cumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloittes 2011 Technology Fast 500™
3. Onyx Pharmaceuticals Announces Third Quarter 2011 Financial Results Teleconference and Webcast
4. Jazz Pharmaceuticals Announces Third Quarter 2011 Results Conference Call on November 1
5. Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
6. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
7. Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
8. Amylin Pharmaceuticals Reports Third Quarter Financial Results
9. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
10. ADVENTRX Pharmaceuticals to Present at the 10th Annual BIOInvestor Forum Conference on October 26
11. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):